A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Status Completed

Clinical Trial Summary

Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain, with GP homology of the gene was only 97.6%, compared to the GP gene of the strain in 1976. This investigational Ad5-EBOV vaccine was developed according to the 2014 epidemic Zaire strain and formulated as freeze-dry products which could be stored at 4℃.

In 2014, a single center, double-blind, placebo control, dose-escalation phase 1 clinical trial was performed in Taizhou, China. Our findings show that the Ad5-EBOV vaccine is safe and robustly immunogenic. One shot of the high dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days. The investigators intent to evaluate the safety and immunogenicity of a booster dose of the recombinant Ebola adenovirus vector vaccine (Ad5-EBOV) in healthy adults after primary immunization in this add in study. The investigators expect that the boosting immunization with a same vaccine for primary immunization is possible and could confer a longer-lived protection when needed.

The phase I trial has been unblind 28 days after the primary vaccination, but all the subjects are still kept blind as well as the laboratory staffs. Therefore, this booster vaccination trial will be conduct in single blind.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02533791
Study type	Interventional
Source	Jiangsu Province Centers for Disease Control and Prevention
Contact
Status	Completed
Phase	Phase 1
Start date	July 2015
Completion date	October 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00374309` - Experimental Vaccine for Prevention of Ebola Virus Infection	Phase 1
Completed	`NCT03098862` - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed	`NCT02509494` - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo	Phase 3
Recruiting	`NCT06093646` - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda	N/A
Completed	`NCT02495246` - A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV	Phase 1
Completed	`NCT04906629` - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees	Phase 1
Completed	`NCT05064956` - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)	Phase 2
Not yet recruiting	`NCT06126822` - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC	Phase 3
Completed	`NCT02267109` - Phase 1 Trial of Ebola Vaccine in Mali	Phase 1
Withdrawn	`NCT04268966` - An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola	Phase 2
Not yet recruiting	`NCT04822376` - Prophylaxis Vaccine Antibodies Ebola	Phase 2
Recruiting	`NCT02333578` - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment	N/A
Completed	`NCT02662855` - Efficacy of Favipiravir Against Severe Ebola Virus Disease	Phase 2
Active, not recruiting	`NCT04152486` - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC	Phase 3
Terminated	`NCT04250168` - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed	`NCT03161366` - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine	Phase 3
Completed	`NCT03140774` - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended	`NCT03462004` - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein	Phase 1
Active, not recruiting	`NCT02876328` - Partnership for Research on Ebola VACcinations	Phase 2
Not yet recruiting	`NCT05202288` - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers	Phase 2